144 related articles for article (PubMed ID: 23982456)
1. 131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study.
Lin CM; Doyle P; Tsan YT; Lee CH; Wang JD; Chen PC;
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):253-9. PubMed ID: 23982456
[TBL] [Abstract][Full Text] [Related]
2. Association Between 131I Treatment for Thyroid Cancer and Risk of Receiving Cataract Surgery: A Cohort Study from Taiwan.
Lin CM; Yeh PT; Doyle P; Tsan YT; Chen PC;
J Nucl Med; 2016 Jun; 57(6):836-41. PubMed ID: 26837336
[TBL] [Abstract][Full Text] [Related]
3. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
[TBL] [Abstract][Full Text] [Related]
4. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study.
Lin CY; Lin CL; Huang WS; Kao CH
J Nucl Med; 2016 May; 57(5):685-90. PubMed ID: 26719377
[TBL] [Abstract][Full Text] [Related]
5. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
6. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
7. Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with Thyroid Cancer: A Nationwide, Population-Based Study in Korea.
Seo GH; Cho YY; Chung JH; Kim SW
Thyroid; 2015 Aug; 25(8):927-34. PubMed ID: 26133388
[TBL] [Abstract][Full Text] [Related]
8. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
9. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
10. Hyperparathyroidism after treatment with radioactive iodine: not only a coincidence?
Bondeson AG; Bondeson L; Thompson NW
Surgery; 1989 Dec; 106(6):1025-7. PubMed ID: 2588108
[TBL] [Abstract][Full Text] [Related]
11. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
[TBL] [Abstract][Full Text] [Related]
12. Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements.
Pacilio M; Bianciardi L; Panichelli V; Argirò G; Cipriani C
Nucl Med Commun; 2005 Jul; 26(7):623-31. PubMed ID: 15942483
[TBL] [Abstract][Full Text] [Related]
13. Epiphora after radioactive iodine therapy in a low-risk patient.
Song H; Jeong J; Ju Koh M
Clin Nucl Med; 2015 Jun; 40(6):536-7. PubMed ID: 25674875
[TBL] [Abstract][Full Text] [Related]
14. Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study.
Seo GH; Kong KA; Kim BS; Kang SY; Moon BS; Yoon HJ; Kim HO
J Clin Endocrinol Metab; 2021 Jun; 106(7):e2580-e2588. PubMed ID: 33755732
[TBL] [Abstract][Full Text] [Related]
15. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma.
Reiners C; Biko J; Haenscheid H; Hebestreit H; Kirinjuk S; Baranowski O; Marlowe RJ; Demidchik E; Drozd V; Demidchik Y
J Clin Endocrinol Metab; 2013 Jul; 98(7):3039-48. PubMed ID: 23616148
[TBL] [Abstract][Full Text] [Related]
16. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma.
Lin JD; Kao PF; Chao TC
Br J Radiol; 1998 Mar; 71(843):307-13. PubMed ID: 9616241
[TBL] [Abstract][Full Text] [Related]
17. [An evaluation of the incidence of hyperparathyroidism after 131I treatment for Basedow disease (Part II)].
Ito K; Tsuchiya T; Sugino K; Murata M
Kaku Igaku; 1996 Jul; 33(7):737-42. PubMed ID: 8803442
[TBL] [Abstract][Full Text] [Related]
18. DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy.
Eberlein U; Scherthan H; Bluemel C; Peper M; Lapa C; Buck AK; Port M; Lassmann M
J Nucl Med; 2016 Feb; 57(2):173-9. PubMed ID: 26564321
[TBL] [Abstract][Full Text] [Related]
19. Association between radioiodine treatment for thyroid cancer and risk of stroke.
Lin CY; Lin CL; Lo YC; Kao CH
Head Neck; 2017 Nov; 39(11):2311-2318. PubMed ID: 28815788
[TBL] [Abstract][Full Text] [Related]
20. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
